In a report released today, Josh Jennings from TD Cowen reiterated a Buy rating on PROCEPT BioRobotics (PRCT – Research Report). The company’s shares closed yesterday at $40.00.
According to TipRanks, Jennings is a 4-star analyst with an average return of 3.7% and a 53.31% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Johnson & Johnson, and Stryker.
Currently, the analyst consensus on PROCEPT BioRobotics is a Strong Buy with an average price target of $44.86, which is a 12.15% upside from current levels. In a report released on December 13, Wells Fargo also maintained a Buy rating on the stock with a $44.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $43.90 and a one-year low of $24.83. Currently, PROCEPT BioRobotics has an average volume of 500.7K.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PRCT in relation to earlier this year. Most recently, in October 2023, Reza Zadno, the President & CEO of PRCT bought 5,148.00 shares for a total of $22,496.76.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PROCEPT BioRobotics (PRCT) Company Description:
PROCEPT BioRobotics Corp is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology.
Read More on PRCT:
- PROCEPT BioRobotics to Present at the 35ᵗʰ Annual Piper Sandler Healthcare Conference in New York City
- Procept BioRobotics price target lowered to $55 from $60 at B. Riley
- Procept BioRobotics raises FY23 revenue view to $133.5M from $131M
- Procept BioRobotics reports Q3 EPS (51c), consensus (53c)
- PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
